Restor3d inks Conformis buyout, adding hip and knee implants to portfolio

Restor3d, which makes 3D-printed devices for spine, ankle and upper extremity procedures, is buying Conformis at a 96% premium. 

By Nick Paul Taylor • June 27, 2023

BD plans $540M sale of surgical instrumentation platform to Steris

The divestiture is part of BD’s strategy to simplify its portfolio and focus on higher-growth markets.

By Peter Green • Updated June 20, 2023

Glass Lewis, joining ISS, supports activist’s candidates for Masimo board

Saying it has “rarely” seen a circumstance where the “need for direct representation of a large shareholder in the boardroom was so apparent,” the proxy advisory firm backed Politan Capital’s bid for two board seats.

By Susan Kelly • June 16, 2023

As Illumina’s deSouza departs, will Grail go next?

The CEO’s resignation could signal a change of direction, as anti-trust regulators order Illumina to divest the liquid biopsy unit.

By Susan Kelly • June 12, 2023

Merit Medical buys two dialysis catheter lines for $132.5M combined

The acquisitions are expected to boost the Utah-based device maker’s annual revenue by about $30 million.

By Susan Kelly • June 9, 2023

SunMed agrees to $110M takeover of Avanos’ respiratory health unit, continuing M&A spree

Avanos, whose competitors include Stryker and Medline Industries, is selling the unit to narrow its focus on areas where it can succeed.

By Nick Paul Taylor • June 9, 2023

Novo Nordisk says in talks to acquire French device-maker Biocorp for $165M

The offer per share is about 20% more than Biocorp’s closing stock price on June 2. The two companies plan to focus on drug delivery solutions for chronic diseases, such as diabetes.

By Elise Reuter • Updated June 6, 2023

Getinge will acquire High Purity for as much as $370M to bolster biopharma business

The acquisition is aimed at strengthening Getinge’s position in the fast-growing area of custom single-use solutions for bioprocessing applications.

By Peter Green • May 31, 2023

Titan licenses robotic surgery intellectual property to Intuitive after failing to find buyer

After failing to bring its surgical robot to market and getting kicked off the Nasdaq, Titan is now marketing its intellectual property.

By Nick Paul Taylor • May 30, 2023

Illumina accused of ‘playing delay tactics’ to push back EU decision on divesting Grail: Financial Times

Delaying the decision to divest Grail could let Illumina sell the liquid biopsy business when the market is more favorable.

By Nick Paul Taylor • May 30, 2023

Boston Scientific cancels $230M stent deal after regulators erect barriers to acquisition

The Federal Trade Commission said Boston Scientific took the action in response to investigations by its staff and overseas enforcement partners.

By Nick Paul Taylor • May 26, 2023

Illumina chair loses to Icahn pick as proxy battle ends

The decision to replace board Chair John Thompson could change the company’s course as it decides whether to divest liquid biopsy company Grail.

By Elise Reuter • Updated May 25, 2023

Medtronic posts profit, sales growth in Q4, agrees to buy Korean diabetes patch maker

The company is “confident in delivering durable revenue growth in the year ahead” amid continued improvements in procedure volumes.

By Peter Green • May 25, 2023

Medtronic agrees to buy Korean insulin patch pump maker for $738m to boost diabetes business

The tubeless, disposable insulin patch made by EOFlow will be integrated into Medtronic’s MiniMed 780G system.

By Elise Reuter • May 25, 2023

A Boston Scientific purchase of Shockwave could be transformative — but at what price?

Boston Scientific has used “tuck-in” acquisitions to boost growth in the past. Some analysts say it should stay the course amid a report the company may make a bid.

By Susan Kelly • May 19, 2023

Icahn bolstered by another proxy advisor in battle with Illumina

The DNA-sequencing company defended its board chair, John Thompson, and drew attention to a new disclosure that Icahn’s firm is being investigated by the U.S. attorney for the Southern District of New York.

By Susan Kelly • Updated May 15, 2023

Baxter to sell biopharma solutions unit for $4.25B to private equity

The company said it plans to use the proceeds of the sale to pay down its debt.

By Elise Reuter • May 8, 2023

Globus shareholders approve share issuance for $3.1B NuVasive purchase

NuVasive’s shareholders also OK’d the merger agreement, bringing the deal a step closer to closing.

By Elise Reuter • April 28, 2023

Quest Diagnostics to pay $450M to buy liquid biopsy cancer test developer as Q1 revenue drops

The laboratory services provider said patients are returning to the healthcare system for routine care, but COVID testing has plummeted as the pandemic winds down.

By Susan Kelly • April 27, 2023

Boston Scientific considering purchase of Shockwave Medical: Bloomberg

The acquisition, which would be Boston Scientific’s largest in recent history, would add to the company’s cardiac portfolio.

By Elise Reuter • April 21, 2023

Alphatec buys robotic spine navigation system for $55M

The spine surgery specialist expects the robotic platform to begin generating revenue in 2025.

By Susan Kelly • Updated April 21, 2023

Illumina slaps back at Icahn’s board nominees, opens proxy collection

The fight continues as Illumina aims to block Icahn’s nominees from ousting its CEO and board chair.

By Peter Green • April 20, 2023

Medtech buyouts by private equity in Q4 shed light on deal-making trends in 2023: report

Medtech companies are continuing to spin off assets to realign portfolios, creating opportunities for private equity firms to buy businesses and exit existing investments.

By Nick Paul Taylor • April 11, 2023

Bioventus CEO departs after CartiHeal acquisition unravels

Ken Reali was asked to leave after a deal to buy CartiHeal fell apart. Bioventus’ share price has fallen more than 90% in the past two years. 

By Susan Kelly • April 6, 2023

Icahn ramps up rhetoric on Illumina after FTC orders Grail sale

In a letter to Illumina shareholders, Icahn says the two companies “should be separated immediately” to protect “long term growth prospects.”

By Peter Green • April 5, 2023